National Heart Institute, Egypt Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2014
NCT02728518
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

National Heart Institute, Egypt

Active Ingredients

Drugs in Phase 3 Trials (1)

ivabradine (corlanor) (1 trial)

Drugs in Other Trials (1)

amikacin (Amikin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Non-ST Elevated Myocardial Infarction (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2